Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors Journal Article
| Authors: | Puc, H. S.; Bajorin, D. F.; Bosl, G. J.; Amsterdam, A.; Motzer, R. J. |
| Article Title: | Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors |
| Abstract: | Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT. © 1995 Kluwer Academic Publishers. |
| Keywords: | adult; clinical article; aged; treatment failure; clinical trial; cisplatin; advanced cancer; antineoplastic agents; topotecan; phase 2 clinical trial; bone marrow suppression; camptothecin; hemoglobin; drug resistance; drug resistance, neoplasm; neutrophil; thrombocyte count; neutrophils; leukocyte count; drugs, investigational; germ cell tumor; hemoglobins; intravenous drug administration; platelet count; middle age; germinoma; human; male; female; priority journal; article; antineoplastic alkaloid; cisplatin-refractory; support, non-u.s. gov't; support, u.s. gov't, p.h.s. |
| Journal Title: | Investigational New Drugs |
| Volume: | 13 |
| Issue: | 2 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1995-06-01 |
| Start Page: | 163 |
| End Page: | 165 |
| Language: | English |
| DOI: | 10.1007/bf00872866 |
| PUBMED: | 8617580 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 28 August 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work